Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial

Usha S Perepu, Isaac Chambers, Abdul Wahab, Patrick Ten Eyck, Chaorong Wu, Sanjana Dayal, Grerk Sutamtewagul, Steven R Bailey, Lori J Rosenstein, Steven R Lentz, Usha S Perepu, Isaac Chambers, Abdul Wahab, Patrick Ten Eyck, Chaorong Wu, Sanjana Dayal, Grerk Sutamtewagul, Steven R Bailey, Lori J Rosenstein, Steven R Lentz

Abstract

Background: Coronavirus disease 2019 (COVID-19) is associated with coagulopathy but the optimal prophylactic anticoagulation therapy remains uncertain and may depend on COVID-19 severity.

Objective: To compare outcomes in hospitalized adults with severe COVID-19 treated with standard prophylactic versus intermediate dose enoxaparin.

Methods: We conducted a multi-center, open-label, randomized controlled trial comparing standard prophylactic dose versus intermediate dose enoxaparin in adults who were hospitalized with COVID-19 and admitted to an intensive care unit (ICU) and/or had laboratory evidence of coagulopathy. Patients were randomly assigned in a 1:1 ratio to receive standard prophylactic dose enoxaparin or intermediate weight-adjusted dose enoxaparin. The primary outcome was all-cause mortality at 30 days. Secondary outcomes included arterial or venous thromboembolism and major bleeding.

Results: A total of 176 patients (99 males and 77 females) underwent randomization. In the intention-to-treat population, all-cause mortality at 30 days was 15% for intermediate dose enoxaparin and 21% for standard prophylactic dose enoxaparin (odds ratio, 0.66; 95% confidence interval, 0.30-1.45; P = .31 by Chi-square test). Unadjusted Cox proportional hazards modeling demonstrated no significant difference in mortality between intermediate and standard dose enoxaparin (hazard ratio, 0.67; 95% confidence interval, 0.33-1.37; P = .28). Arterial or venous thrombosis occurred in 13% of patients assigned to intermediate dose enoxaparin and 9% of patients assigned to standard dose enoxaparin. Major bleeding occurred in 2% of patients in each arm.

Conclusion: In hospitalized adults with severe COVID-19, standard prophylactic dose and intermediate dose enoxaparin did not differ significantly in preventing death or thrombosis at 30 days.

Keywords: COVID-19 disease; anticoagulant; blood coagulation; enoxaparin; thrombosis.

© 2021 International Society on Thrombosis and Haemostasis.

Figures

FIGURE 1
FIGURE 1
Screening, enrollment, randomization and populations analyzed.
FIGURE 2
FIGURE 2
Time to event (cumulative incidence) plot of the probability of death for all patients in the intention‐to‐treat population. In an unadjusted Cox proportional hazard model, the hazard ratio for mortality in the intermediate dose group compared with the standard dose group was 0.67; 95% confidence interval, 0.33 to 1.37, P = 0.28. The dotted lines indicate the 95% confidence interval bands.

References

    1. Miesbach W., Makris M. COVID‐19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clin Appl Thromb Hemost. 2020;26 doi: 10.1177/1076029620938149.
    1. Connors J.M., Levy J.H. COVID‐19 and its implications for thrombosis and anticoagulation. Blood. 2020;135:2033–2040. doi: 10.1182/blood.2020006000.
    1. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844–847. doi: 10.1111/jth.14768.
    1. Al‐Samkari H., Karp Leaf R.S., Dzik W.H., et al. COVID‐19 and coagulation: bleeding and thrombotic manifestations of SARS‐CoV‐2 infection. Blood. 2020;136:489–500. doi: 10.1182/blood.2020006520.
    1. Jimenez D., Garcia‐Sanchez A., Rali P., et al. Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta‐analysis. Chest. 2021;159:1182–1196. doi: 10.1016/j.chest.2020.11.005.
    1. Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18:1094–1099. doi: 10.1111/jth.14817.
    1. Nadkarni G.N., Lala A., Bagiella E., et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID‐19. J Am Coll Cardiol. 2020;76:1815–1826. doi: 10.1016/j.jacc.2020.08.041.
    1. Rentsch C.T., Beckman J.A., Tomlinson L., et al. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. BMJ. 2021;372 doi: 10.1136/bmj.n311.
    1. Vaughn V.M., Yost M., Abshire C., et al. Trends in venous thromboembolism anticoagulation in patients hospitalized with COVID‐19. JAMA Netw Open. 2021;4 doi: 10.1001/jamanetworkopen.2021.11788.
    1. Thachil J., Juffermans N.P., Ranucci M., et al. ISTH DIC subcommittee communication on anticoagulation in COVID‐19. J Thromb Haemost. 2020;18:2138–2144. doi: 10.1111/jth.15004.
    1. Spyropoulos A.C., Levy J.H., Ageno W., et al. Scientific and Standardization Committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID‐19. J Thromb Haemost. 2020;18:1859–1865. doi: 10.1111/jth.14929.
    1. Barnes G.D., Burnett A., Allen A., et al. Thromboembolism and anticoagulant therapy during the COVID‐19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis. 2020;50:72–81. doi: 10.1007/s11239-020-02138-z.
    1. Cuker A., Tseng E.K., Nieuwlaat R., et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID‐19. Blood Adv. 2021;5:872–888. doi: 10.1182/bloodadvances.2020003763.
    1. Flaczyk A., Rosovsky R.P., Reed C.T., Bankhead‐Kendall B.K., Bittner E.A., Chang M.G. Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: implications for clinical practice and future investigations. Crit Care. 2020;24:559. doi: 10.1186/s13054-020-03273-y.
    1. INSPIRATION Investigators. Sadeghipour P., Talasaz A.H., et al. Effect of intermediate‐dose vs standard‐dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID‐19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA. 2021;325(16):1620–1630. doi: 10.1001/jama.2021.4152.
    1. ATTACC. ACTIV‐4a & REMAP‐CAP multiplatform RCT: results of interim analysis. National Heart, Lung, and Blood Institute. Published January 28, 2021.
    1. Toh C.H., Hoots W.K., SSC on DIC of the ISTH The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5‐year overview. J Thromb Haemost. 2007;5:604–606. doi: 10.1111/j.1538-7836.2007.02313.x.
    1. Harris P.A., Taylor R., Thielke R., Payne J., Gonzalez N., Conde J.G. Research electronic data capture (REDCap)–a metadata‐driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–381. doi: 10.1016/j.jbi.2008.08.010.
    1. Schulman S., Kearon C., Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients. J Thromb Haemost. 2005;3:692–694. doi: 10.1111/j.1538-7836.2005.01204.x.
    1. Schulz K.F., Altman D.G., Moher D., Group C CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340 doi: 10.1136/bmj.c332.
    1. Talasaz A.H., Sadeghipour P., Kakavand H., et al. Recent randomized trials of antithrombotic therapy for patients with COVID‐19: JACC state‐of‐the‐art review. J Am Coll Cardiol. 2021;77:1903–1921. doi: 10.1016/j.jacc.2021.02.035.
    1. Malas M.B., Naazie I.N., Elsayed N., Mathlouthi A., Marmor R., Clary B. Thromboembolism risk of COVID‐19 is high and associated with a higher risk of mortality: A systematic review and meta‐analysis. EClinicalMedicine. 2020;29 doi: 10.1016/j.eclinm.2020.100639.
    1. Tritschler T., Mathieu M.E., Skeith L., et al. International Network of VTCRNI‐VTE. Anticoagulant interventions in hospitalized patients with COVID‐19: A scoping review of randomized controlled trials and call for international collaboration. J Thromb Haemost. 2020;18:2958–2967. doi: 10.1111/jth.15094.
    1. Wiersinga W.J., Rhodes A., Cheng A.C., Peacock S.J., Prescott H.C. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID‐19): a review. JAMA. 2020;324:782–793. doi: 10.1001/jama.2020.12839.
    1. Klok F.A., Kruip M., van der Meer N.J.M., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID‐19. Thromb Res. 2020;191:145–147. doi: 10.1016/j.thromres.2020.04.013.
    1. Middeldorp S., Coppens M., van Haaps T.F., et al. Incidence of venous thromboembolism in hospitalized patients with COVID‐19. J Thromb Haemost. 2020;18:1995–2002. doi: 10.1111/jth.14888.
    1. Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
    1. Fox S.E., Akmatbekov A., Harbert J.L., Li G., Quincy Brown J., Vander Heide R.S. Pulmonary and cardiac pathology in African American patients with COVID‐19: an autopsy series from New Orleans. Lancet Respir Med. 2020;8:681–686. doi: 10.1016/S2213-2600(20)30243-5.
    1. Dolhnikoff M., Duarte‐Neto A.N., de Almeida Monteiro R.A., et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID‐19. J Thromb Haemost. 2020;18:1517–1519. doi: 10.1111/jth.14844.
    1. Manne B.K., Denorme F., Middleton E.A., et al. Platelet gene expression and function in patients with COVID‐19. Blood. 2020;136:1317–1329. doi: 10.1182/blood.2020007214.
    1. Hottz E.D., Azevedo‐Quintanilha I.G., Palhinha L., et al. Platelet activation and platelet‐monocyte aggregate formation trigger tissue factor expression in patients with severe COVID‐19. Blood. 2020;136:1330–1341. doi: 10.1182/blood.2020007252.
    1. Zuo Y., Estes S.K., Ali R.A., et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID‐19. Sci Transl Med. 2020;12 doi: 10.1126/scitranslmed.abd3876.
    1. Zuo Y., Yalavarthi S., Shi H., et al. Neutrophil extracellular traps in COVID‐19. JCI Insight. 2020;5 doi: 10.1172/jci.insight.138999.
    1. Lopes R.D., de Barros E.S.P.G.M., Furtado R.H.M., et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID‐19 and elevated D‐dimer concentration (ACTION): an open‐label, multicentre, randomised, controlled trial. Lancet. 2021;397:2253–2263. doi: 10.1016/S0140-6736(21)01203-4.
    1. Berger J.S., Connors J.M. Anticoagulation in COVID‐19: reaction to the ACTION trial. Lancet. 2021;397:2226–2228. doi: 10.1016/S0140-6736(21)01291-5.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe